Breast Cancer

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of biosimilars in oncology.

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses caveats of the PERSEPHONE trial.

The FDA has approved the Magtrace and Sentimag Magnetic Localization System used to guide lymph node biopsies in women undergoing mastectomy for breast cancer.

Naamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses the future landscape of radiation oncology.

We traveled to Houston, Texas for a State of the Science Summit on Breast Cancer on July 11, 2018. The conference covered radiation therapy, triple-negative breast cancer, BRCA-positive tumors, takeaways from the 2018 ASCO Annual Meeting, and more.

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine and Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, discusses ongoing research in triple-negative breast cancer (TNBC).

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.

Researchers remain keenly interested in exploring PIK3CA as an anticancer target in breast cancer.

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.

The FDA has granted a priority review designation to a biologics license application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer following at least 2 prior therapies for metastatic disease.

The FDA has approved upfront ribociclib for use in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer. The agency also approved the CDK 4/6 inhibitor for use in combination with fulvestrant for the treatment of postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer, in the frontline setting or after disease progression on endocrine therapy.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.

In a groundbreaking study of costs and quality of cancer care among cancer clinics in the state of Washington, investigators found wide disparity in end-of-life care, suggesting that improvements in cost and quality could be attained if treatment centers share information on what works and endeavor to improve.

Yelena Novik, MD, discusses the application of CDK4/6 inhibition and methods to overcome resistance in ER-positive breast cancer.